GLP-1 & Incretin Science

Lean Mass Loss on GLP-1 Therapy, and the BELIEVE Result

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Weight lost on incretin therapy is not all fat. In the Phase 2 BELIEVE trial, adults on semaglutide alone lost 7.4% of lean mass; adding bimagrumab reduced that to 2.9% while producing greater total reduction of 22.1%, of which 92.8% was fat mass.

Key facts

Lean loss, semaglutide alone
7.4%
Lean loss, plus bimagrumab
2.9%
Total reduction, combination
22.1%
Fat share of that loss
92.8%
Lean fraction of total loss
~21% → ~7%
Bimagrumab target
Activin type II receptor
Trial
BELIEVE, Phase 2, published in Nature Medicine

Why the composition of weight loss matters

A scale reports mass, not what the mass was. Skeletal muscle contributes to metabolic rate, glucose disposal, physical function and, in older populations, to the ability to remain independent. Losing a substantial fraction of it alongside fat is a materially different outcome from losing fat alone, even when the headline percentage is identical.

How much lean mass is involved

Reported estimates run as high as 40% of total weight lost coming from lean tissue, though figures vary with population, measurement method and duration. In the BELIEVE trial specifically, semaglutide alone produced 7.4% lean mass loss, corresponding to roughly 21% of total weight lost. Different studies produce different numbers, and body-composition measurement methods are not interchangeable.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What bimagrumab is

Bimagrumab is a monoclonal antibody against the activin type II receptor. Blocking that receptor interrupts myostatin and activin signalling, the pathway that restrains skeletal muscle growth. Inhibiting a brake on muscle mass is a mechanistically different intervention from anything the incretins do, which is why it combines with them rather than competing.

The BELIEVE result

Adding bimagrumab to semaglutide reduced lean mass loss from 7.4% to 2.9%, while total reduction reached 22.1% with 92.8% of it fat mass. Expressed as a fraction, the lean share of total loss fell from roughly 21% to about 7%. The combination therefore produced more total reduction and a substantially better composition, which is an unusual pairing of outcomes.

How to read this cautiously

BELIEVE is Phase 2. Body composition is a surrogate: better composition is assumed to translate into better function and outcomes, and that assumption is reasonable but not demonstrated by this trial. A 2026 systematic review and meta-analysis in Diabetes, Obesity and Metabolism examined bimagrumab in obesity and metabolic dysfunction more broadly, and the activin/myostatin pathway as a muscle-preservation target has its own 2026 review literature.

Why this became a prominent question in 2026

As incretins moved toward 20% and beyond, the absolute quantity of tissue lost grew with them. At 5% reduction the composition question is academic; at 25% it is not. The compounds getting more effective is what made this a live issue rather than a footnote.

Quick reference

Semaglutide aloneSemaglutide + bimagrumab
Lean mass lost7.4%2.9%
Total weight reductionLower22.1%
Fat share of loss~79%92.8%
Lean share of loss~21%~7%

Frequently asked questions

Do all GLP-1 drugs cause lean mass loss?

Weight loss from any cause includes some lean tissue. The question is the proportion, which varies by compound, population, duration and measurement method.

How does bimagrumab work?

It is an antibody against the activin type II receptor, blocking myostatin and activin signalling, the pathway that limits skeletal muscle mass.

Is bimagrumab approved?

No. BELIEVE is a Phase 2 trial and the compound holds no marketing authorisation.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.